CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA THERAPEUTICS MARKET ANALYSIS, 2020 - 2027

1. Chemotherapy-induced Thrombocytopenia Therapeutics Chemotherapy-induced Thrombocytopenia Therapeutics Market, by Drug Class (Thrombopoietin Receptor Market, by Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), by Route Agonists, Thrombopoietic Agents, and Others), by Route of Administration (Oral and Injectable), by Distribution of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 2027 Cancer is a major chronic disease, which can be managed and treated by chemotherapy, radiation therapy, immunotherapy, hormone therapy, stem cell transplant, targeted therapy, and other therapies. Cancer can be treated by using one therapy or by using combination of therapies based on the stage, type of cancer, and other factors. Chemotherapy is the type of treatment, where the drugs are used to stop or slow the growth of cancer cells. Chemotherapy- induced thrombocytopenia is a serious complication in the chemotherapy-treated patients. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Impact of Coronavirus Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Impact of Coronavirus (COVID – 19) Pandemic (COVID – 19) Pandemic The COVID-19 pandemic is expected to restrain the global chemotherapy-induced thrombocytopenia therapeutics market growth during the forecast period. The COVID-19 pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector has been impacted

2. majorly due to the COVID-19 pandemic. The shutdown has disrupted the supply, distribution, and manufacture of medical supplies globally. Moreover, due to social distancing, the footfall in clinics and health institutions has fallen by over 70% during this pandemic, which has led to decrease in number of chemotherapy procedures, which has negatively impacted the market growth. Furthermore, the coronavirus pandemic has hampered the development, clinical trials, production, and supply of drugs and other healthcare products and also have affected growth of the healthcare businesses of various companies across the globe. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. As a result, the impact of the COVID-19 pandemic is expected to limit growth of the market during the forecast period. The global chemotherapy-induced thrombocytopenia therapeutics market is estimated to be valued at US$ 1,168.4 million US$ 1,168.4 million in 2020 2020 and is expected to exhibit a CAGR of 4.5% forecast period (2020-2027). (2020-2027). 4.5% during the Get PDF Brochure Of This Research Report @ : Get PDF Brochure Of This Research Report @ : https://www.coherentmarketinsights.com/insight/request-pdf/4332 https://www.coherentmarketinsights.com/insight/request-pdf/4332 Increasing incidence of cancer is expected to drive growth of the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period. Rising cancer cases is expected to increase the number of chemotherapy procedures and thereby expected to drive the chemotherapy-induced thrombocytopenia therapeutics market growth over the forecast period. For instance, according to the World Cancer Research Fund International’s report in 2018, the total number of cancer cases worldwide was around 17,036,901 in 2018. Moreover, rising approvals from regulatory agencies such as the U.S. Food and Drug Administration (FDA) aiding in speedy approval by designating the orphan drug status to drugs targeted to benefit patients with rare disease is expected to boost the market growth. For

3. instance, in December 2019, Dova Pharmaceuticals, Inc., a subsidiary of Swedish Orphan Biovitrum AB received the Orphan Drug Designation grant from the U.S. Food and Drug Administration (FDA) for avatrombopag, a treatment for chemotherapy-induced thrombocytopenia (CIT). Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Restraints Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Restraints Lack of approved drugs or therapeutics for the chemotherapy-induced thrombocytopenia is the major factor that is expected to hinder the market growth. Currently, Oprelvekin-recombinant interleukin-11 (IL-11) is the only thrombopoietic agent approved by the U.S. Food and Drug Administration for the treatment of chemotherapy-induced thrombocytopenia. It is indicated for adults with solid tumors and lymphomas associated with severe chemotherapy-induced thrombocytopenia. Uncertainty of advancement of drug clinical trials and failure of therapeutics is the major factor that is expected to restrain the market growth over the forecast period. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Regional Analysis Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Regional Analysis On the basis of region, the global chemotherapy-induced thrombocytopenia therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

4. North America is expected to dominate the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period, owing to increasing cancer cases in the region. For instance, according to the Cancer Treatment & Survivorship Facts & Figures 2019-2021 Report published by the American Cancer Society, Inc., the estimated number of cancer cases in U.S. was around 16,920,370, as of 1st January 2019. Research Methodology Research Methodology Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include: Primary Research (Trade Surveys and Experts Interviews) Primary Research (Trade Surveys and Experts Interviews) • Desk Research Desk Research • Proprietor Data Analytics Model Proprietor Data Analytics Model • In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings. Request Sample Copy of Research Report @ : Request Sample Copy of Research Report @ : https://www.coherentmarketinsights.com/insight/request-sample/4332 https://www.coherentmarketinsights.com/insight/request-sample/4332 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Competitive Landscape Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Competitive Landscape

5. Some of the key players operating in the global chemotherapy-induced thrombocytopenia global chemotherapy-induced thrombocytopenia therapeutics market include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., therapeutics market include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum) Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum) About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com Email: sales@coherentmarketinsights.com